Mount Sinai joins MMRC to develop new treatments for multiple myeloma

NewsGuard 100/100 Score

The Multiple Myeloma Research Consortium (MMRC) and Mount Sinai School of Medicine today announced that Mount Sinai has become the newest Member Institution to join the MMRC to accelerate the development of new treatments for multiple myeloma.

“Mount Sinai is honored to be recognized by the MMRC for our contributions to groundbreaking research in multiple myeloma”

The MMRC brings together leading academic institutions to promote and facilitate collaborative research in multiple myeloma, an incurable blood cancer with one of the lowest five-year survival rates of any cancer. Through its clinical research model, the MMRC has opened 25 clinical trials to date. MMRC members are among the world's leading clinical research institutions in multiple myeloma. Mount Sinai School of Medicine's involvement in the MMRC follows the June appointment of blood cancer expert, Dr. Sundar Jagannath, MD, as Director of the Multiple Myeloma Program and Professor of Hematology and Medical Oncology at Mount Sinai School of Medicine's Tisch Cancer Institute. Based on its membership, Mount Sinai School of Medicine will conduct Phase I and II clinical trials in multiple myeloma, as well as contribute to the MMRC Tissue Bank, which houses a critical mass of highly-annotated tissue and peripheral blood samples from multiple myeloma patients, and serves as a bridge between laboratory and clinical research.

"Mount Sinai School of Medicine was invited to join the MMRC as a Member Institution based on specific criteria, including extensive experience in conducting clinical trials and research in multiple myeloma. We are excited to welcome Mount Sinai School of Medicine, and look forward to working in partnership with them and the rest of our Consortium membership to bring new therapies to patients as quickly as possible," said Susan L. Kelley, MD, Chief Medical Officer of the MMRC. "We are also pleased to continue our long-standing relationship with Dr. Jagannath and his team, whose work is dedicated to improving outcomes for multiple myeloma patients."

An internationally known researcher, Dr. Jagannath has published more than 180 peer-reviewed articles in top journals including the New England Journal of Medicine, Blood, the Journal of Clinical Oncology, the British Journal of Haematology, and Cancer. As Director for the Multiple Myeloma Program at Mount Sinai, Dr. Jagannath is helping to develop the Multiple Myeloma and Stem Cell Transplant Program into a translational and clinical research center in multiple myeloma. He is building projects that bridge basic science and clinical practices for the benefit of advancing care in blood cancer.

"Mount Sinai is honored to be recognized by the MMRC for our contributions to groundbreaking research in multiple myeloma," said Dr. Jagannath. "Together with the other institutions in this prestigious consortium, we will make great strides in the treatment of this devastating disease."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Linking lifestyle to longevity: How diet and hypertension sway risks for heart disease and cancer